$RXRX

Recursion Pharmaceuticals (RXRX) shares rose 5.81% on AI-driven drug discovery progress. The company reported $74.3M revenue, negative margins, and $545M in cash. Genentech optioned a neuroscience target, and RXRX cut FY26 spending to $375M, extending cash runway to early 2028. Analysts have mixed views, with an average price target of $7.22.

Recursion Pharmaceuticals (RXRX) shares rose 5.77% after announcing a collaboration and updating Q2 2026 results. The company reported a net loss of $131M, beating estimates, with $7.3M in revenue. RXRX cut 2026 spending to $375M, extending its cash runway to early 2028. Analysts have mixed views, with an average price target of $7.22. The company's AI drug-discovery platform gained traction with Genentech's involvement and pipeline advancements.

Recursion Pharmaceuticals (RXRX) shares rose 8.2% since last earnings report, outperforming the S&P 500. Q2 2026 earnings showed a loss of 25 cents per share, wider than estimates, with revenues falling 60% YoY to $7.67M. Operating costs decreased, and cash reserves are expected to last into early 2028. Analyst estimates have shifted 6.51% in the past month.

MindWalk Holdings Corp. (HYFT) reported a 46% revenue increase to C$15.6M, with improved margins and narrowed losses. The company focuses on AI-enabled drug discovery, emphasizing its data and systems of record. Comparatively, Veeva Systems (VEEV) rose after strong earnings, while Certara (CERT) and Recursion (RXRX) fell due to missed expectations, highlighting market preference for proprietary data.

Recursion Pharmaceuticals (RXRX) stock rose 7.23% after reporting AI-driven drug discovery progress and cost-cutting measures. The company reported Q2 2026 revenue of $7.7M and a net loss of $131M, with $545M in cash. Analysts have mixed views, with a mean price target of $7.22. RXRX is focusing on AI-driven drug development and has partnerships with companies like Genentech.

Recursion Pharmaceuticals (RXRX) stock rose 7.61% after positive AI-driven drug discovery results. The company reported Q2 2026 revenue of $7.7M, a net loss of $131M, and $545M in cash. It reduced its FY26 expense guidance to $375M, extending its cash runway into early 2028. Analysts have mixed views, with a consensus target of $7.22.

Recursion Pharmaceuticals (RXRX) is under scrutiny for its clinical pipeline and AI platform. Key milestones include Phase 2 data for REC-4881 and early results for REC-1245, with partnerships potentially unlocking milestone payments. The company's cash burn extends runway into early 2028. Investors debate the AI platform's ability to deliver consistent clinical wins. Q2 revenue missed expectations, and insiders have sold shares. Institutional investors have mixed positions, with some adding and

Simply Wall St reports Recursion Pharmaceuticals (RXRX) shares fell after its 2Q and first-half 2026 results showed sharply lower sales and revenue, though net loss narrowed year over year. The article cites RXRX down 4.53% (1 day) and 1.86% (7 days). It also notes a “fair value” of $1.97 versus $3.16 and a DCF cash-flow value of $9.80.

Benzinga reports Jim Cramer’s comments alongside recent earnings updates. Vistra missed Q2 revenue and EPS estimates but grew adjusted EBITDA and reaffirmed full-year outlook. Recursion Pharmaceuticals reported worse-than-expected Q2 results. NextEra Energy had mixed Q2 results and reaffirmed guidance. Huntington Ingalls beat Q2 results and raised FY26 sales guidance. Fastly’s Q2 EPS beat estimates. Shares moved modestly.

Recursion (RXRX) discussed Q2 2026 progress on its internal pipeline and partnerships. It cited FDA engagement and upcoming Phase II updates for REC-4881, IND clearance for REC-7735, and continued Phase I dose escalation for REC-1245. With Roche-Genentech, it announced a first neuroscience target entering a joint early discovery program, and said it has achieved over $260M in upfront and milestones with potential for $300M+ more per program.